Skip to content
PubMed This is a summary of 17 peer-reviewed journal articles Updated
Endocrinology

The Path to Diagnosis: Testing and Timelines

At a Glance

After a traumatic brain injury, early hormone results can be temporary or misleading. A full pituitary evaluation is commonly done at 3–6 months, repeated around 12 months, and followed by dynamic growth hormone testing later when needed.

Following a traumatic brain injury (TBI), the process of diagnosing hormonal issues is a marathon, not a sprint. Because the brain undergoes significant chemical and physical changes during recovery, a single blood test taken shortly after your injury rarely tells the whole story. To get an accurate diagnosis, doctors follow a specific timeline and set of “challenge” tests to see how your pituitary gland is actually functioning.

Why Early Testing Can Be Misleading

In the days and weeks immediately following a head injury, your body enters a state of high stress. During this acute phase, your brain intentionally shifts hormone production to prioritize survival [1].

  • The Stress Response: Critically ill patients often have suppressed thyroid and sex hormones as the body tries to conserve energy. These “abnormal” results are often a normal reaction to trauma and critical illness, and do not mean you have permanent pituitary damage [2][3].
  • The Exceptions: The critical exceptions involve evaluating for adrenal and water-balance issues. Deficiencies in cortisol (adrenal) and arginine vasopressin (central diabetes insipidus) can be life-threatening and require clinical assessment and treatment even in the first few days, though vasopressin is not checked via a direct blood test [4][5].
  • Transient Deficiencies: Many people show pituitary issues in the first month that completely vanish by the six-month mark as the brain heals [6][7].

A Common Surveillance Framework

Because PTPD is “dynamic”—meaning it can improve or even appear for the first time months later—medical consensus suggests a structured screening framework for anyone with a moderate-to-severe TBI or a symptomatic mild TBI [2][8].

  1. 3 to 6 Months Post-Injury: This is commonly considered the first reliable window for a comprehensive “baseline” evaluation of all pituitary axes [9].
  2. 12 Months Post-Injury: A repeat evaluation is frequently recommended. Studies show that while some early deficiencies resolve, approximately 16% of patients may develop new hormone failures between 3 and 12 months [10][6].
  3. Long-term: If new symptoms like extreme fatigue or weight changes emerge years later, testing should be revisited, as some pituitary issues can have a very late onset [11].

Essential Testing: The “Paired” Approach

To diagnose a central deficiency (one caused by the pituitary gland rather than the target organ), doctors must measure the pituitary signal and the target hormone at the same time.

  • Central Hypothyroidism: They check TSH (the pituitary signal) and Free T4 (the thyroid hormone). In central hypothyroidism, your TSH might look inappropriately “normal” or low, but your Free T4 is low, meaning the pituitary isn’t sending a strong enough signal [12].
  • Adrenal: They check ACTH (the signal) and Morning Cortisol. Because cortisol levels peak in the morning, blood must be drawn between 8:00 AM and 9:00 AM to be valid, accounting for sleep schedule and medications [5]. Prolactin and sodium/osmolality testing may also be added when appropriate.
  • Sex Hormones: They pair LH/FSH with Testosterone (for men) or Estradiol (for women). Men often require repeat morning testing, and interpretation for women depends on menstrual or menopausal status [12].

The “Challenge” of Growth Hormone Testing

Diagnosing Growth Hormone (GH) Deficiency is particularly complex. You cannot diagnose it with a simple, random blood draw because GH is released in “pulses” throughout the day and night [13].

  • The IGF-1 Trap: Doctors often check IGF-1 as a proxy for GH. However, in TBI patients, a “normal” IGF-1 does not rule out a deficiency. Many patients with confirmed GH failure have IGF-1 levels that appear perfectly normal on paper [13][14].
  • Dynamic Stimulation Testing: To get a definitive answer, you may undergo a “provocative” or dynamic stimulation test. This involves taking a medication under specialist supervision (like glucagon, macimorelin, or insulin) that challenges the pituitary to release GH. These tests carry contraindications, and insulin tolerance testing induces hypoglycemia, so test choice is individualized [15][16].
  • Why Wait?: Specialists usually delay dynamic GH testing until at least 6 to 12 months after your injury. Testing too early may lead to unnecessary treatment, as the GH axis is often the most likely to recover on its own [17][9].

Common questions in this guide

When should pituitary hormones be checked after a traumatic brain injury?
Adrenal and water-balance problems may need assessment in the first days after an injury because they can be dangerous. A broader pituitary evaluation is commonly performed at 3 to 6 months and repeated around 12 months. Testing may be repeated later if symptoms such as severe fatigue or weight changes appear.
Can an abnormal hormone test soon after a TBI prove that I have permanent pituitary damage?
No. Acute trauma and critical illness can temporarily alter thyroid and sex hormone levels, and some deficiencies found during the first month resolve by six months. Results should be interpreted in light of timing, symptoms, medications, and overall medical condition.
Why do doctors measure pituitary signals and target hormones together?
Pituitary hormones act as signals that tell organs such as the thyroid, adrenal glands, and reproductive organs what to do. Measuring the signal and the target hormone at the same time helps show whether a problem starts in the pituitary or in the target organ. For example, TSH is interpreted together with free T4 when checking for central hypothyroidism.
What is the best time of day to test ACTH and cortisol after a head injury?
ACTH and morning cortisol are generally measured between 8:00 AM and 9:00 AM, when cortisol is normally near its daily peak. Sleep schedule, medications, and illness can affect interpretation, so follow your clinician’s instructions. A borderline result may lead to a supervised stimulation test, such as a cosyntropin test, using the appropriate assay-specific interpretation.
Does a normal IGF-1 result rule out growth hormone deficiency after a TBI?
No. People with traumatic brain injuries can have growth hormone deficiency even when their IGF-1 level is within the usual range. A supervised dynamic stimulation test is often needed, and specialists commonly wait at least 6 to 12 months after the injury because growth hormone function may recover.
Why is a dynamic test needed to diagnose growth hormone deficiency?
Growth hormone is released in pulses, so a random blood test cannot reliably show how much the body produces. A dynamic test uses a medicine such as glucagon, macimorelin, or insulin under specialist supervision to challenge the pituitary. The choice depends on contraindications and health risks, and insulin testing can cause low blood sugar.
Can pituitary problems appear after an initially normal recovery from a TBI?
Yes. Pituitary function can recover, worsen, or change during the first year, and some people develop new hormone deficiencies between 3 and 12 months. Later testing may be appropriate if new or persistent symptoms develop, even after an earlier normal result.

Get notified when new evidence is published on Post-traumatic pituitary deficiency.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (17)
  1. 1

    [Stress adaptive effects after traumatic brain injury].

    Teryaeva NB, Moshkin AV

    Zhurnal voprosy neirokhirurgii imeni N. N. Burdenko 2016; (80(3)):114-117 doi:10.17116/neiro2016803114-117.

    PMID: 28635848
  2. 2

    [Hypopituitarism after traumatic brain injury].

    Carmona R C, Villanueva G P, Huete I, et al.

    Revista medica de Chile 2020; (148(12)):1796-1805 doi:10.4067/S0034-98872020001201796.

    PMID: 33844746
  3. 3

    Systemic manifestations of traumatic brain injury.

    Gaddam SS, Buell T, Robertson CS

    Handbook of clinical neurology 2015; (127()):205-18.

    PMID: 25702219
  4. 4

    Pathophysiology and diagnosis of neuroendocrine abnormalities in patients with traumatic brain injury.

    Feldt-Rasmussen U, Klose MC

    Best practice & research. Clinical endocrinology & metabolism 2025; (39(3)):102020 doi:10.1016/j.beem.2025.102020.

    PMID: 40592688
  5. 5

    Cortisol evaluation during the acute phase of traumatic brain injury-A prospective study.

    Bensalah M, Donaldson M, Aribi Y, et al.

    Clinical endocrinology 2018; (88(5)):627-636 doi:10.1111/cen.13562.

    PMID: 29405355
  6. 6

    Pituitary function within the first year after traumatic brain injury or subarachnoid haemorrhage.

    Tölli A, Borg J, Bellander BM, et al.

    Journal of endocrinological investigation 2017; (40(2)):193-205 doi:10.1007/s40618-016-0546-1.

    PMID: 27671168
  7. 7

    Navigating anterior pituitary dysfunction after traumatic brain injury: mechanisms, diagnosis, and management.

    Ren X, Su J, Shi W, et al.

    Acta neurologica Belgica 2025; doi:10.1007/s13760-025-02948-z.

    PMID: 41254442
  8. 8

    Clinical manifestations and treatment of hypopituitarism due to traumatic brain injury.

    Zhang CD, Ioachimescu AG

    Best practice & research. Clinical endocrinology & metabolism 2025; (39(3)):101996 doi:10.1016/j.beem.2025.101996.

    PMID: 40280796
  9. 9

    Approach to the Patient With Traumatic Brain Injury-induced Pituitary Dysfunction.

    Kelestimur F, Agha A, Ioachimescu AG, et al.

    The Journal of clinical endocrinology and metabolism 2026; (111(6)):e1695-e1707 doi:10.1210/clinem/dgag090.

    PMID: 41782180
  10. 10

    Plasminogen Activator Inhibitor Type 1: A Possible Novel Biomarker of Late Pituitary Dysfunction after Mild Traumatic Brain Injury.

    Frendl I, Katko M, Galgoczi E, et al.

    Journal of neurotrauma 2017; (34(23)):3238-3244 doi:10.1089/neu.2017.5198.

    PMID: 28931364
  11. 11

    Delayed onset arginine vasopressin deficiency after traumatic brain injury.

    Tomulescu SA, Boto J, Gariani K

    Endocrinology, diabetes & metabolism case reports 2024; (2024(4)).

    PMID: 39475774
  12. 12

    Clinical and diagnostic approach to patients with hypopituitarism due to traumatic brain injury (TBI), subarachnoid hemorrhage (SAH), and ischemic stroke (IS).

    Karamouzis I, Pagano L, Prodam F, et al.

    Endocrine 2016; (52(3)):441-50 doi:10.1007/s12020-015-0796-2.

    PMID: 26573924
  13. 13

    Utility of serum IGF-1 for diagnosis of growth hormone deficiency following traumatic brain injury and sport-related concussion.

    Lithgow K, Chin A, Debert CT, Kline GA

    BMC endocrine disorders 2018; (18(1)):20 doi:10.1186/s12902-018-0247-1.

    PMID: 29609574
  14. 14

    Detection of Growth Hormone Deficiency in Adults with Chronic Traumatic Brain Injury.

    Kreber LA, Griesbach GS, Ashley MJ

    Journal of neurotrauma 2016; (33(17)):1607-13 doi:10.1089/neu.2015.4127.

    PMID: 26414093
  15. 15

    Current concepts of the diagnosis of adult growth hormone deficiency.

    Tritos NA, Biller BMK

    Reviews in endocrine & metabolic disorders 2021; (22(1)):109-116 doi:10.1007/s11154-020-09594-1.

    PMID: 32959175
  16. 16

    AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF GROWTH HORMONE DEFICIENCY IN ADULTS AND PATIENTS TRANSITIONING FROM PEDIATRIC TO ADULT CARE.

    Yuen KCJ, Biller BMK, Radovick S, et al.

    Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 2019; (25(11)):1191-1232 doi:10.4158/GL-2019-0405.

    PMID: 31760824
  17. 17

    Growth Hormone Deficiency Following Traumatic Brain Injury.

    Kgosidialwa O, Hakami O, Muhammad Zia-Ul-Hussnain H, Agha A

    International journal of molecular sciences 2019; (20(13)) doi:10.3390/ijms20133323.

    PMID: 31284550

This page is for informational purposes only and does not constitute medical advice. An endocrinologist or other qualified clinician should interpret your results and recommend testing for your situation.